Avacta Therapeutics
  • About
  • Our Science
  • Pipeline
  • News
  • Investors
  • Careers
  • Contact
  • About
    • About Avacta
    • Leadership
    • Intellectual Property
  • Our Science
    • Our Science
    • 1st Gen
    • 2nd Gen
    • 3rd Gen
    • Partners
    • Clinical trials
  • Pipeline
  • News
  • Investors
    • Investors
    • Key info
    • Corporate Governance
    • Resources
    • Publications
    • Share price
    • RNS News
    • Events
    • Research
  • Careers
    • Job vacancies
    • Benefits of working at Avacta
  • Contact
  • About
    • About Avacta
    • Leadership
    • Intellectual Property
  • Our Science
    • Our Science
    • 1st Gen
    • 2nd Gen
    • 3rd Gen
    • Partners
    • Clinical trials
  • Pipeline
  • News
  • Investors
    • Investors
    • Key info
    • Corporate Governance
    • Resources
    • Publications
    • Share price
    • RNS News
    • Events
    • Research
  • Careers
    • Job vacancies
    • Benefits of working at Avacta
  • Contact
Home News Diagnostics
filter by: view all | Avacta Academy | Blogs | Diagnostics | Investors | Podcasts and Videos | R&D Spotlights Series | Therapeutics

Diagnostics

01 Sep 2025

Avacta Announces Completion of the Sale of Coris Bioconcept SRL

Diagnostics | Investors
28 Jul 2025

Avacta Announces Agreement to Sell Coris Bioconcept SRL

Diagnostics | Investors
25 Mar 2025

Avacta Announces Completion of the Sale of Launch Diagnostics

Diagnostics | Investors
07 Mar 2025

Avacta Announces Agreement to Sell Launch Diagnostics and a Corporate Update

Diagnostics | Investors
01 Jun 2023

Avacta acquires Coris Bioconcept, adding a broad range of marketed professional-use rapid tests to the Group

Diagnostics | Investors
18 Oct 2022

Proposed placing, open offer and issue of convertible bonds

Diagnostics | Investors
18 Oct 2022

Proposed acquisition of Launch Diagnostics

Diagnostics | Investors
10 Jan 2022

Update on AffiDX® SARS-CoV-2 antigen lateral flow test and detection of the Omicron variant

Diagnostics | Investors
22 Dec 2021

AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Receives CE Mark for Consumer Self-Testing

Diagnostics | Investors
15 Dec 2021

AffiDX® SARS-CoV-2 antigen lateral flow test detects the Omicron variant

Diagnostics | Investors

Posts navigation

Older posts
Avacta Therapeutics
  • Terms of Use
  • Terms & Conditions
  • Privacy Policy
  • Intellectual Property
  • Corporate Responsibility
  • Contact Us

Avacta Group plc

Scale Space,  White City
Imperial College Campus
58 Wood Lane
London
W12 7RZ

+44 (0)20 3911 0353

Investor Enquiries

Cohesion Bureau

 

Email

Twitter | Linkedin

©2026 Avacta Therapeutics. Registered company no. 06605196.